Current Oncology | Free Full-Text | Endometrial Cancer: Transitioning from Histology to Genomics
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in
Dostarlimab in Advanced/Recurrent Mismatch Repair Deficient/Microsatellite Instability High or Proficient/Stable Endometrial Can
GARNET: Dostarlimab in EC - Slideset Download - Clinical Oncology 2022 | CCO
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 | International Journal of Gynecologic Cancer
Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients - Oncology Central
Dostarlimab: First Approval | SpringerLink
GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer - CancerConnect
Cancer Trial Results
Cancer Trial Results
Biomolecules | Free Full-Text | Dostarlimab: A Review
Immune-Related End Points Consistent With Traditional Measurements of Dostarlimab in Non-Endometrial dMMR Solid Tumors
From New Molecular Insights to New Treatment Options in Endometrial Cancer | Published in healthbook TIMES Oncology Hematology
GSK announces positive data for endometrial cancer drug dostarlimab - Pharmaceutical Technology
The Time Course of Adverse Events During Dostarlimab Treatment in Patients with Recurrent or Advanced Endometrial Cancer in the
Current Oncology | Free Full-Text | Endometrial Cancer: Transitioning from Histology to Genomics
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer - Plain Language Summaries
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study - ScienceDirect
ESMO 2022: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study
272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study | International Journal of Gynecologic Cancer
Expert Commentary On The Product Profile Of Dostarlimab
